[Clinical use of virally inactived plasma. The experience of Blood Transfusion Unit in Mantova, Italy]. (2013)

Peer-Reviewed Study · Lepri D, Capuzzo E, Mattioli AV, Dall'Oglio D, Sgarioto V, Terenziani I, Caramaschi G, Manzato F et al. · March 2013

Lepri D et al., 2013-03: Italian 2013 report from the Mantova blood transfusion unit on the clinical use of virally inactivated plasma, naming methylene blue among the available inactivation methods; the comparison the unit monitored was solvent-detergent plasma (Plasmasafe) against a historical cohort of single-donor fresh frozen plasma.

The DMTE (Blood Transfusion Unit) in Mantova has used the pharmaceutical-like SD virally inactivated plasma since 2007 (Plasmasafe, Kedrion) as replacement of the PFC by each single donor.

106-11

Lepri D et al., 2013-03: Italian 2013 report from the Mantova blood transfusion unit on the clinical use of virally inactivated plasma, naming methylene blue among the available inactivation methods; the comparison the unit monitored was solvent-detergent plasma (Plasmasafe) against a historical cohort of single-donor fresh frozen plasma. C7 Italy (Recenti Prog Med 104(3):106-11). Study type: institutional observational/usage comparison. Methylene blue viral inactivation named as one of the technical procedures; the unit's own practice switched to solvent-detergent plasma (Plasmasafe, Kedrion) in 2007, so the methylene-blue product is described as the comparator rather than the product adopted. Funder/conflicts not stated. Records the Italian hospital use of methylene-blue plasma; not evidence of clinical superiority.